Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 15/20 | 0.45 |
| ▸ | CA1 | P00915 | 14/20 | 0.45 |
| ▸ | CA9 | Q16790 | 13/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23652150 | 1.00 | CA2 (0.48) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL14172499 | 1.00 | CA2 (0.48) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL14172495 | 0.92 | CYP2D6 (0.51) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL13944649 | 0.91 | CA2 (0.40) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL22328419 | 0.91 | CA2 (0.40) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL14172498 | 0.89 | CA12 (0.45) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL23740302 | 0.87 | CA2 (0.48) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL23652136 | 0.87 | CA2 (0.48) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL13943527 | 0.87 | CA2 (0.48) | CA2CYP2D6THRBHSD17B10CA12 | |
| SCHEMBL15927236 | 0.86 | CA12 (0.42) | CA2CYP2D6THRBHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2024-02-29 | — | — | US | disclosed |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2021-12-16 | — | — | US | disclosed |
| EP-2862581-B1 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LP (CA) | 2021-08-11 | — | — | EP | disclosed |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2021-06-01 | — | — | US | disclosed |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | Bellus Health, Inc. (CA) | 2020-12-08 | — | — | US | disclosed |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2020-08-13 | — | — | US | disclosed |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2019-03-26 | — | — | US | disclosed |
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC. (CA) | 2017-04-06 | — | — | US | disclosed |
| US-9499480-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2016-11-22 | — | — | US | disclosed |
| EP-2862581-A2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI Limited Partnership (CA) | 2015-04-22 | — | — | EP | disclosed |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI LIMITED PARTNERSHIP (CA) | 2014-08-07 | — | — | US | disclosed |
| US-8748656-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2014-06-10 | — | — | US | disclosed |
| US-8748656-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2014-06-10 | — | — | US | disclosed |
| WO-2009019534-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA2 1659/4885CYP2D6 602/4885THRB 4606/4885 |
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA2 1611/4885CYP2D6 637/4885THRB 4622/4885 |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | CA2 1558/4885CYP2D6 528/4885THRB 4668/4885 |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | CA2 1558/4885CYP2D6 528/4885THRB 4668/4885 |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA2 1659/4885CYP2D6 602/4885THRB 4606/4885 |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA2 1659/4885CYP2D6 602/4885THRB 4606/4885 |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | DNPEP, DAO, APP | CA2 2017/4885CYP2D6 28/4885THRB 2061/4885 |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA2 1659/4885CYP2D6 602/4885THRB 4606/4885 |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | CA2 1558/4885CYP2D6 528/4885THRB 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.